Every 10-Q that GRI Bio, Inc. (GRI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GRI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GRI filings page.
GRI Bio, Inc. is a clinical-stage biopharmaceutical company developing immunology-based therapies, led by GRI-0621 for idiopathic pulmonary fibrosis (IPF). For the quarter ended June 30, 2026, it reported a net loss of $1.6 million, narrower than the prior-year period, with operating expenses of $1.6 million driven by reduced research and development spending following completion of a Phase 2a trial of GRI-0621. For the six-month period, the net loss was $3.6 million.
Cash and cash equivalents were $10.9 million as of June 30, 2026, and the accumulated deficit was $55.3 million. The company raised capital mainly through an at-the-market program, selling 1,688,546 shares in the first half of 2026 for $8.2 million in gross proceeds, and additional 2025 public offerings with common stock and warrants. Management believes existing cash funds operations through the second quarter of 2027 under a limited development plan, but states there is substantial doubt about its ability to continue as a going concern without additional financing.
GRI-0621 received FDA Orphan Drug Designation for IPF on June 18, 2026, following a Phase 2a trial that met its primary safety endpoint and showed supportive biomarker and functional trends. The company also continues early work on GRI-0803 for autoimmune diseases. GRI remains a smaller reporting and emerging growth company and discloses an ongoing material weakness in internal controls, with revised controls in place but not yet operating for a sufficient period. A new, stayed Nasdaq Market Value of Listed Securities requirement, if implemented, could pose delisting risk because the company’s MVLS is currently below the proposed threshold.
GRI Bio, Inc. reported a Q1 2026 net loss of $1.998M, narrowing from $3.046M a year earlier, as research and development spending fell to $0.361M from $1.64M after completing a Phase 2a trial of lead drug GRI-0621. General and administrative expenses rose to $1.642M, reflecting higher public company costs.
The company ended March 31, 2026 with $11.048M in cash and cash equivalents, helped by $6.8M of gross proceeds from an at-the-market stock program during the quarter. Management believes this cash funds operations into the second quarter of 2027 but warns it is insufficient to complete a Phase 2b trial of GRI-0621 without substantial additional capital. The filing states there is “substantial doubt” about GRI Bio’s ability to continue as a going concern absent new financing.
GRI Bio, Inc. filed its Q3 2025 10-Q, reporting a quarterly net loss of $3,359 on operating expenses of $3,365 (both in thousands). Cash and cash equivalents were $4,055, with management stating resources are sufficient into the first quarter of 2026 and disclosing substantial doubt about the ability to continue as a going concern without additional financing.
Year to date, operating cash use was $7,215, partially offset by financing inflows, including $5,000 from April 2025 offering proceeds and $2,560 through the ATM program (gross, in thousands). The company increased additional paid-in capital to $51,030 and ended the quarter with stockholders’ equity of $1,993 (in thousands). As of November 13, 2025, 3,268,727 common shares were outstanding.
GRI continues a Phase 2a biomarker study of GRI-0621 in IPF, with topline results expected by the end of November 2025. The pipeline also includes GRI-0803, with further progress dependent on funding.
GRI Bio is a clinical-stage biopharmaceutical company advancing oral iNKT/dNKT modulators. The company reported a net loss of $2.89 million for the quarter and $5.94 million for the six months ended June 30, 2025, driven by higher research and development spending on GRI-0621 ($1.88 million in Q2; $3.52 million six months) and ongoing company overhead.
Cash and cash equivalents were $5.12 million at period end; management forecasts this funding will support operations into the fourth quarter of 2025 but discloses substantial doubt about going concern without additional financing. Clinical progress includes completion of Phase 2a enrollment in July 2025, an Independent Data Monitoring Committee review reporting no safety concerns for early cohorts, and topline biomarker results expected in Q3 2025. Recent financings include an April 2025 offering (net $4.02 million) and ATM sales (net $4.29 million through June 30, 2025). The company disclosed a material weakness in internal controls.